Dabigatran use for cardioversion of persistent atrial fibrillation or atrial flutter without transoesophageal echocardiography was safe, with zero major cardiac or embolic events occurring over a mean follow-up of 19.4 months.
Cohort (n=82)
No
Does dabigatran allow safe cardioversion without transoesophageal echocardiography in patients with persistent atrial fibrillation or atrial flutter?
Dabigatran appears safe for facilitating cardioversion in patients with persistent atrial fibrillation or flutter without the need for prior transoesophageal echocardiography.
BACKGROUND AND AIM: To assess the safety of dabigatran in converting persistent atrial fibrillation (PAF) and atrial flutter (AFL) to sinus rhythm (SR) without transoesophageal echocardiography (TEE) evaluation. METHODS: Consecutive patients with PAF or AFL were included between 2012 and 2015. Dabigatran was used for three weeks before and six months after cardioversion. Left atrium area (LAA) and left atrium volume (LAV) were assessed in all patients. Follow-up visits for major cardiac events occurred at 1, 3, 6, and 12 months. RESULTS: The study included 82 patients (56 male, mean age 63.1 ± 10.4 years), of which 45 had PAF and 37 AFL. In patients with PAF, mean LAA was 30.3 ± 5.3 cm2 and LAV 114.4 ± 31.5 mL; in those with AFL mean LAA was 26.5 ± 4.2 cm2 and LAV 97 ± 24.9 mL at baseline. Forty-nine patients underwent uncomplicated electric cardioversion (38 with PAF and 11 with AFL), 11 patients were pharmacologically converted to SR (7 with PAF and 4 with AFL), and 22 patients with AFL underwent successful radiofrequency ablation. The mean CHA2DS2-VASc score was 2.96 ± 1.39 (score > 3, 58.6%). No major cardiac events occurred during the follow-up period of 19.4 ± 9.5 months. CONCLUSIONS: Safe cardioversion using dabigatran was achieved in this small group of patients without the need for TEE.
Cozma et al. (2015) conducted a cohort in Persistent atrial fibrillation (PAF) or atrial flutter (AFL) (n=82). Dabigatran was evaluated on Major cardiac events (stroke, systemic or pulmonary embolism, myocardial infarction, major bleeding, and death). Dabigatran use for cardioversion of persistent atrial fibrillation or atrial flutter without transoesophageal echocardiography was safe, with zero major cardiac or embolic events occurring over a mean follow-up of 19.4 months.